What type of medication is Mounjaro (Tirzepatide)?

Mounjaro, which is the brand name for Tirzepatide, is classified as a dual agonist that activates both the GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) receptors. This dual action is referred to as a "twincretin" mechanism. The activation of these two pathways enhances glucose-dependent insulin secretion, suppresses glucagon release, and promotes satiety, making it effective for managing blood glucose levels in individuals with type 2 diabetes.

The GLP-1 component is well-established in its ability to promote weight loss and improve glycemic control, while the addition of GIP activity is believed to further enhance these effects. This unique profile distinguishes Tirzepatide from other diabetes medications that target only one of these pathways or different mechanisms entirely.

Recognizing this important feature is key for understanding how Mounjaro functions and its potential advantages in diabetes management compared to other treatment options.